Last updated: July 27, 2026
DAYTRANA is the branded transdermal methylphenidate patch marketed by Corium (historically Shire; branded via previous commercialization entities). The product competes in ADHD with oral immediate- and extended-release methylphenidate and amphetamine regimens, and with other transdermal options in the category (notably AZEDAY for methylphenidate transdermal system in some markets) depending on geography and approval status. High-intent market demand is driven by pediatric and adolescent ADHD prevalence, persistence to therapy, payer coverage for long-acting formulations, and caregiver preference for adherence-optimized delivery.
Featured snippet answers (quick take)
- Clinical trials (recent): Publicly available registries do not show a clear wave of new, late-stage (Phase 3) DAYTRANA-specific trials completed in the last cycle comparable to NME launches; ongoing activity is more consistent with label maintenance, formulation/process work, or comparative/PK studies that support existing regulatory positions.
- Near-term growth drivers: Formulary access for long-acting methylphenidate options, switching among long-acting ADHD therapies by payers, and continued need for non-oral delivery in a subset of patients.
- Exclusivity and projection posture: DAYTRANA’s forecast is governed primarily by (1) patent/market exclusivity timelines and (2) transdermal methylphenidate product competition rather than by a new clinical differentiation program.
DAYTRANA clinical trials update: what new studies exist and what endpoints matter?
Answer: The available public clinical-trial record footprint for DAYTRANA is dominated by legacy development and regulatory support (pharmacokinetics, dose-response, and safety in pediatric/adolescent ADHD), with fewer signals of new, pivotal Phase 3 programs. Most updates that move the market are tied to regulatory lifecycle events (labeling, manufacturing changes, or compatibility with evolving ADHD standards) rather than major new efficacy readouts.
What trial types have historically supported DAYTRANA’s label?
- Pediatric ADHD efficacy using DSM-based assessments and clinician-rated scales typical for ADHD development programs.
- Pharmacokinetics and dose proportionality for transdermal delivery.
- Safety/tolerability with focus on skin reactions, appetite suppression, sleep impact, and cardiovascular monitoring norms for stimulants.
- Treatment adherence and caregiver usability outcomes are often secondary and reflected in persistence to therapy rather than single pivotal endpoints.
What should investors watch in the next registry cycles?
- PK/BE studies for process or formulation changes.
- Real-world evidence publications and payer utilization studies that can shift uptake between transdermal versus oral delivery.
- Comparative adherence and discontinuation analyses that can influence managed care contracting decisions.
Clinical-trials update and market impact are linked less to “new efficacy” and more to whether DAYTRANA retains or loses plan position versus competing long-acting ADHD products.
What is DAYTRANA’s FDA regulatory status and Orange Book posture?
Answer: DAYTRANA is an FDA-approved transdermal methylphenidate product. The competitive and generic risk for DAYTRANA depends on Orange Book patent listings and any Paragraph IV challenges tied to those listings. Market projections should be anchored to the earliest expiration date among listed patents and any associated regulatory exclusivities.
How to interpret Orange Book listings for a transdermal stimulant
- Patents can cover:
- composition/formulation (drug in patch matrix)
- transdermal delivery system design (rate-controlling components)
- methods of use (dosing regimens or therapeutic timing)
- manufacturing/process steps
- Litigation posture affects launch timing more than headline expiration dates alone.
What does this mean for market timing?
- If Orange Book lists composition/formulation patents expiring later, generics face delayed market entry even if basic regulatory exclusivity lapses earlier.
- If method-of-use patents remain active, a “skinner” launch strategy using different labeling language can fail or trigger injunction risk.
(Orange Book status and specific listing numbers cannot be stated here without a citation-backed extraction of the DAYTRANA listing set.)
When does DAYTRANA lose exclusivity and what expiration dates drive generic risk?
Answer: Exclusivity-based projections for DAYTRANA should use the earliest of:
- the earliest expiration date among relevant listed Orange Book patents, and
- any applicable regulatory exclusivities tied to the reference product and/or supplement approvals.
Because the question is timeline-critical, the forecast hinges on a correct mapping of the earliest expiry and the expected lead time for generic development and FDA review.
How expiration translates into market decline
- Generic pipeline lead times: Developing transdermal drug products involves formulation iteration, adhesive/matrix optimization, and stability work that can extend timelines beyond oral generics.
- Payer adoption cycles: Even with approval, utilization changes can be slow due to prior authorization, brand preference programs, and patient switching reluctance.
- Injunction/settlement effects: If patents are actively litigated, entry can be delayed by settlement terms or enjoined pending trial outcomes.
(Exact dates require Orange Book and litigation docket extraction for DAYTRANA.)
How many patents protect DAYTRANA and what types are most relevant for a generic launch?
Answer: For transdermal methylphenidate systems, the most launch-sensitive patents are typically formulation/delivery-system and manufacturing patents, with method-of-use patents affecting label alignment. The number of patents and their categories must be read from the Orange Book listing set.
Patent category risk ranking for transdermal systems
- Formulation and delivery system patents (hard to design around without performance equivalence issues)
- Manufacturing/process patents (changes can trigger infringement risk if covered steps are reused)
- Method-of-use/dosing regimen patents (can be worked around through label carve-outs, if permitted)
- Skin/adhesion performance patents (reformulation barriers can be high)
(Again, the actual count and numbers require listing-specific extraction.)
Which generic or transdermal methylphenidate products compete with DAYTRANA?
Answer: DAYTRANA competes against long-acting methylphenidate products and amphetamine extended-release regimens, plus other transdermal methylphenidate options where approved and marketed. In a market forecast, the most meaningful competitive constraint is not “any generic,” but the availability of a payer-preferred alternative in the same delivery category with equivalent duration and tolerability.
Competitive set (category-level)
- Oral extended-release methylphenidate brands and authorized generics
- Oral amphetamine extended-release regimens
- Other transdermal methylphenidate systems by brand and/or region
Switching friction and uptake
- Transdermal can win for:
- adherence in children who resist oral dosing
- caregiver preference for fewer dosing events per day
- Transdermal can lose for:
- skin irritation or patch tolerance issues
- inconsistent duration in real-world use versus pill-based regimens
What patent litigation affects DAYTRANA and how do Paragraph IV challenges change launch timing?
Answer: Patent litigation and any Paragraph IV filings determine whether generic or AB-rated products enter at or after the earliest listed patent expiry. Settlement terms can push launch beyond statutory timelines. Without a dossier extraction of the DAYTRANA dockets and Orange Book filing history, listing the specific litigation cases is not feasible in a factual way here.
How to model litigation impact in projections
- Identify:
- earliest listed patent expiry
- whether an ANDA was filed with Paragraph IV certifications
- whether a court entered an injunction or a delayed entry trigger
- settlement “no earlier than” dates if present
Then apply:
- probability-weighted launch timing scenarios
- expected erosion curves based on formulary adoption rates
How strong is the patent estate for DAYTRANA and what is the risk of design-around?
Answer: For transdermal systems, design-around risk tends to be higher in formulation and delivery-system patents because therapeutic effect depends on drug release kinetics and skin contact mechanics. A strong estate typically delays entry and limits “drop-in” generic substitutes until performance can be demonstrated.
What makes transdermal patent estates difficult to circumvent
- adhesive composition
- rate-controlling membrane/matrix structure
- manufacturing controls tied to drug release profiles
- stability and patch-integrity performance
Formulation and delivery: what parts of DAYTRANA’s transdermal design matter for IP and ANDA approval?
Answer: The transdermal methylphenidate system’s performance depends on:
- matrix/adhesive chemistry that governs drug diffusion to the skin
- patch adhesion and wear time consistency
- skin-interface design affecting local exposure and systemic absorption
What regulators and ANDA filers typically must match
- in vitro release and in vivo bioequivalence profiles
- dosing duration and systemic exposure (AUC, Cmax, Tmax patterns)
- safety signals including dermatologic reactions
These elements are frequently tied to formulation patents and manufacturing process claims.
Market analysis: how big is the ADHD patch opportunity and where does DAYTRANA fit?
Answer: DAYTRANA’s opportunity is the subset of ADHD treated with transdermal long-acting methylphenidate systems (plus patient overlap with oral regimens). Market size is constrained by:
- payer coverage and prior authorization barriers
- treatment preference between transdermal and oral delivery
- safety/tolerability experiences and persistence
Demand drivers by segment
- Pediatric ADHD (6-17): Largest growth pool for stimulant therapy, with patch uptake dependent on caregiver adherence concerns.
- Adherence-optimized patients: Higher likelihood to switch into patch delivery.
- Managed care dynamics: Competitive contracting favors products with strong access and robust real-world persistence.
Supply-side constraints
- transdermal drug manufacturing complexity
- stability and patch integrity distribution logistics
Market projection for DAYTRANA: base, downside, and upside scenarios by exclusivity and payer adoption
Answer: Projections should be anchored to the two-phase pattern common to branded specialty products:
- steadily shrinking share due to ongoing generic/competition substitution in the class
- step-down risk when the product faces a clear regulatory or exclusivity end-state
Scenario framework (structure for use in forecasting)
- Base case: Continued share retention driven by transdermal niche preference; gradual erosion from oral long-acting generics and other branded options.
- Downside case: Early or credible generic entry (or a settlement-driven launch date) plus payer formulary switching.
- Upside case: Delay to entry due to litigation/patent constraints and/or sustained plan access paired with strong persistence.
A numerical projection is not provided here because it requires (1) current revenue run-rate and (2) an identified exclusivity/Orange Book and litigation timeline set for DAYTRANA.
How does DAYTRANA compare with other ADHD long-acting options on performance and switching economics?
Answer: Transdermal methylphenidate competes on adherence and caregiver dosing convenience, while oral extended-release competes on supply simplicity, established prescriber preference, and broad plan formularies. In practice, switching is driven by patient-specific tolerability and administrative burden.
Switching triggers in real-world adoption
- dermatologic tolerance
- day-to-day symptom control and duration fit
- appetite suppression and sleep effects
- insurance coverage and copay support availability
Economic unit drivers
- net price after rebates under payer contracts
- patient out-of-pocket under tiers
- prior authorization success rates and denial impacts
Key Takeaways
- DAYTRANA’s near-term outlook is determined less by new pivotal clinical development and more by regulatory lifecycle events, patent estate strength, and payer formulary position.
- Competitive pressure in ADHD is persistent across oral and transdermal options; patch uptake depends on adherence needs and tolerability.
- Market projections should be built on Orange Book expiry dates and any litigation/settlement “no earlier than” launch constraints, not on general ADHD market growth alone.
FAQs
- What is the difference between DAYTRANA and oral extended-release methylphenidate for ADHD dosing duration?
- Can transdermal methylphenidate reduce caregiver dosing burden compared with pills and how does that affect persistence?
- What typical safety signals (skin reactions, appetite suppression, sleep) matter most for transdermal stimulant use?
- What are the most common reasons payers restrict patch-based ADHD therapies versus oral generics?
- How do patent litigation settlements generally affect generic entry timing for drug-device delivery systems like transdermal patches?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (DAYTRANA listing pages).
- ClinicalTrials.gov (DAYTRANA and methylphenidate transdermal system search results).
